Fungus in the Gut 
October 18, 2016
Brain Cancer: Causes, Symptoms & Treatment
October 19, 2016
Show all

FDA Warns on Hepatitis C Drugs

Certain hepatitis C medications could cause hepatitis B to reactivate.

The Food and Drug Administration is warning about the risk of reactivation of hepatitis B among patients who have had that disease and who are taking some prominent and expensive newer medicines for hepatitis C.

The federal agency said it is requiring a so-called black-box warning in the labels for at least nine brand-name direct-acting antiviral drugs, including Sovaldi and Harvoni from Gilead Sciences Inc., Viekira Pak from AbbVie Inc. and Zepatier from Merck & Co. That is the most serious kind of warning that can be levied by the FDA.

The agency said serious liver problems or death occurred in “a few cases.” These medicines are already threatening the budgets of private and government insurers and of prison systems because of list prices ranging from $54,000 to $94,000 a person for a typical 12-week course. Hepatitis C infects millions of Americans and can lead to death after decades in the body.

Read Full Article: FDA Warns on Hepatitis C Drugs – WSJ

Read Full Article: FDA Warns on Hepatitis C Drugs – WSJ

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.